(2:10) Frank's background – Stanford, Palantir, Google, Calico, now Stately Bio

(4:35) What Stately Bio does – Marrying brightfield imaging with modern ML for live cell analysis

(8:10) Why brightfield imaging matters – Cheap, live, centuries-old tech meets new machine learning

(12:05) Real-time monitoring and forecasting biological outcomes

(18:20) How living cell observation shrinks iteration cycles

(24:45) Applications to stem cell therapies: diabetes, Parkinson’s, liver, heart, kidney

(30:10) ML advantage – Machine vision finds subtle signals invisible to humans

(35:50) Stately Bio’s early success – New York Blood Center partnership

(40:25) The cost advantage of imaging vs. single-cell omics

(44:30) Platform vs pipeline – Why Stately is building therapies, not just a tool

(50:00) Future verticals: Biomanufacturing, synthetic biology applications

(54:50) Frank’s journey – From coder to founder to biotech CEO

(1:00:05) Challenges in filtering conflicting advice as a founder

(1:04:40) Surprise learnings from scaling Stately

(1:09:00) ISCT conference announcements – New breakthroughs in suspension cells imaging

(1:13:25) Big vision – Starting the phenomics revolution through live-cell analysis